Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 known ✓ | Q12809 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.46 |
| ▸ | DNM1 | Q05193 | 3/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | GPX4 | P36969 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5713117 | 1.00 | MAPT (0.49) | MAPTMCHR1DNM1KCNH2CNR2 | |
| Hydrochloric Acid SCHEMBL5713125 | 1.00 | MAPT (0.49) | MAPTMCHR1DNM1KCNH2CNR2 | |
| SCHEMBL26025426 | 0.98 | MAPT (0.50) | MAPTMCHR1DNM1KCNH2CNR2 | |
| SCHEMBL26256139 | 0.98 | MAPT (0.50) | MAPTMCHR1DNM1KCNH2CNR2 | |
| SCHEMBL12573122 | 0.98 | MAPT (0.50) | MAPTMCHR1DNM1KCNH2CNR2 | |
| SCHEMBL14947358 | 0.98 | MAPT (0.50) | MAPTMCHR1DNM1KCNH2CNR2 | |
| SCHEMBL28526661 | 0.98 | MAPT (0.50) | MAPTMCHR1DNM1KCNH2CNR2 | |
| SCHEMBL13261438 | 0.96 | MAPT (0.51) | MAPTMCHR1DNM1KCNH2CNR2 | |
| SCHEMBL8484830 | 0.90 | MAPT (0.58) | MAPTMCHR1KCNH2CNR2ALDH1A1 | |
| SCHEMBL16520720 | 0.90 | ALDH1A1 (0.50) | MAPTMCHR1KCNH2CNR2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12370352-B2 | Nasal and ophthalmic delivery of aqueous corticosteroid solutions | CYDEX PHARMACEUTICALS, INC. (US) | 2025-07-29 | — | — | US | disclosed |
| US-20220339414-A1 | NASAL AND OPHTHALMIC DELIVERY OF AQUEOUS CORTICOSTEROID SOLUTIONS | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2022-10-27 | — | — | US | disclosed |
| EP-2173169-B1 | NASAL DELIVERY OF AQUEOUS CORTICOSTEROID SOLUTIONS | CYDEX PHARMACEUTICALS INC (US) | 2014-05-21 | — | — | EP | disclosed |
| EP-2173169-A1 | NASAL AND OPHTHALMIC DELIVERY OF AQUEOUS CORTICOSTEROID SOLUTIONS | CyDex Pharmaceuticals, Inc. (US) | 2010-04-14 | — | — | EP | disclosed |
| US-20090312724-A1 | Nasal and Ophthalmic Delivery of Aqueous Corticosteroid Solutions | CYDEX PHARMACEUTICALS, INC. (US) | 2009-12-17 | — | — | US | disclosed |
| WO-2009003199-A1 | NASAL AND OPHTHALMIC DELIVERY OF AQUEOUS CORTICOSTEROID SOLUTIONS | CYDEX PHARMACEUTICALS, INC. (US) | 2008-12-31 | — | — | WO | disclosed |
| US-7344783-B2 | Durable hydrophobic surface coatings using silicone resins | SHELL OIL COMPANY (US) | 2008-03-18 | — | — | US | disclosed |
| EP-1215226-B1 | Diene-based rubber/inorganic compound complexes, methods for producing the same and rubber compositions containing the same | JSR CORP (JP) | 2006-06-07 | — | — | EP | disclosed |
| EP-1660601-A1 | DURABLE HYDROPHOBIC SURFACE COATINGS USING SILICONE RESINS | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005112883-A1 | PRESERVED PHARMACEUTICAL COMPOSITIONS COMPRISING CYCLODEXTRINS | ALLERGAN, INC. (US) | 2005-12-01 | — | — | WO | disclosed |
| US-6969706-B1 | Preserved pharmaceutical compositions comprising cyclodextrins | ALLERGAN, INC. (US) | 2005-11-29 | — | — | US | disclosed |
| US-20050256083-A1 | Ophthalmic liquid containing a cyclodextrin, a guanidine-based cationic compound, and sorbic acid | ALLERGAN, INC. (US) | 2005-11-17 | — | — | US | disclosed |
| WO-2005007764-A1 | DURABLE HYDROPHOBIC SURFACE COATINGS USING SILICONE RESINS | SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ B.V. (NL) | 2005-01-27 | — | — | WO | disclosed |
| US-20050009953-A1 | Durable hydrophobic surface coatings using silicone resins | PENNZOIL-QUAKER STATE COMPANY | 2005-01-13 | — | — | US | disclosed |
| US-20040214797-A1 | Preserved pharmaceutical compositions comprising cyclodextrins | ALLERGAN, INC. | 2004-10-28 | — | — | US | disclosed |
| US-6740704-B2 | UNIFORM DISPERSION | JSR CORPORATION (JP) | 2004-05-25 | — | — | US | disclosed |
| US-20020111418-A1 | Methods for producing diene-based rubber/inorganic compound complexes and rubber compositions containing the same | JSR CORPORATION (JP) | 2002-08-15 | — | — | US | disclosed |
| EP-1215226-A2 | Diene-based rubber/inorganic compound complexes, methods for producing the same and rubber compositions containing the same | JSR Corporation (JP) | 2002-06-19 | — | — | EP | disclosed |
| US-5998488-A | PREVENT ADSORPTION OF MICROBIOCIDES BY CONTACT LENSES; MIXTURE CONTAINING BORIC ACID, ETHYLENEDIAMINE AND A CYCLODEXTRIN | LION CORPORATION (JP) | 1999-12-07 | — | — | US | disclosed |
| US-5425804-A | Modified organic silicone oil; polishing agent for the coated surfaces of automobiles and for plastics, rubbers and glass | TAIHO INDUSTRIES CO., LTD. (JP) | 1995-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214797-A1 | Preserved pharmaceutical compositions comprising cyclodextrins | DDOST, RPN1, GANC | KCNH2 2132/4885MAPT 818/4885MCHR1 3202/4885 |
| US-20090312724-A1 | Nasal and Ophthalmic Delivery of Aqueous Corticosteroid Solutions | CRH, HRH1, IL5 | KCNH2 1760/4885MAPT 1791/4885MCHR1 101/4885 |
| US-20050256083-A1 | Ophthalmic liquid containing a cyclodextrin, a guanidine-based cationic compound, and sorbic acid | SORBS1, GANC, UACA | KCNH2 1229/4885MAPT 216/4885MCHR1 4087/4885 |
| US-12370352-B2 | Nasal and ophthalmic delivery of aqueous corticosteroid solutions | CRH, HRH1, IL5 | KCNH2 1760/4885MAPT 1791/4885MCHR1 101/4885 |
| US-20220339414-A1 | NASAL AND OPHTHALMIC DELIVERY OF AQUEOUS CORTICOSTEROID SOLUTIONS | CRH, HRH1, IL5 | KCNH2 1760/4885MAPT 1791/4885MCHR1 101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.